In short
From HPV primary screening to colposcopy, biopsy, CIN grading and LEEP or cold-knife conisation — a plain-language walkthrough of how cervical pre-cancer is found and treated in China.
What this guide covers: Terms that appear on reports · Screening · Colposcopy · Pathology · Treatment by grade
Cervical cancer is one of the most preventable cancers there is, because the pre-cancerous phase lasts years and can be detected and treated. The Chinese clinical guideline for cervical lesions sets out the whole chain: who is screened, with what test, how abnormal results are triaged, and how confirmed disease is treated and followed.
Terms that appear on reports
Cervical intraepithelial neoplasia, or CIN, is graded CIN1, CIN2 and CIN3. Low-grade squamous intraepithelial lesion (LSIL) corresponds to CIN1; high-grade squamous intraepithelial lesion (HSIL) corresponds to CIN2 and CIN3. Adenocarcinoma in situ, or AIS, is the glandular equivalent. Endocervical curettage is ECC; LEEP is loop electrosurgical excision; CKC is cold-knife conisation.
Screening
Women aged 25 to 64 are screened with high-risk HPV testing every five years, with cytology used to triage positive results. Women aged 21 to 24 are screened with cytology alone every three years — HPV primary screening is not recommended in that group because of the high rate of transient infection. Women over 65 can stop if prior screening has been adequate and normal, but those with a history of CIN2 or worse continue for twenty years.
Women living with HIV are screened annually with both tests, other immunosuppressed women annually with cytology, and during pregnancy only clearly abnormal findings are investigated — ECC and conisation are contraindicated.
Tests used are validated HPV assays detecting fourteen high-risk types, cytology reported in the Bethesda system, co-testing where both are done together, and self-sampled HPV for women in areas with poor access, which performs close to clinician-collected samples.
Colposcopy
Referral follows defined triggers: cytology of ASC-US or worse with positive high-risk HPV; ASC-H or worse regardless of HPV status; AGC, AIS or cancer on cytology; HPV 16 or 18 positivity, which can be referred directly; and clinical suspicion such as contact bleeding or a visible lesion. Acute infection, menstruation and pregnancy — for ECC — are contraindications.
The procedure follows a standard sequence: saline to visualise the original squamocolumnar junction, 5 percent acetic acid with assessment of acetowhitening after a minute, Lugol's iodine to map non-staining areas, and a green filter to examine abnormal vessels. Two to four targeted biopsies are taken from the worst area, with ECC where indicated, and specimens are orientated by clock position.
A colposcopy is described as adequate or inadequate depending on whether the whole junction and the whole lesion are visible, and findings are graded with a Swede score, with five or above suggesting high-grade disease.
Pathology
Grading distinguishes CIN1 with atypia confined to the lower third, CIN2 involving the lower two-thirds with diffuse p16 positivity, and CIN3 with full-thickness atypia and intact basement membrane. Microinvasive carcinoma is defined as stromal invasion of 3 mm or less with horizontal spread of 7 mm or less. Reports must state specimen type, grade, margin status with orientation, and lymphovascular space involvement.
Treatment by grade
CIN1 is largely managed by observation — repeat cytology at twelve months in younger women, HPV testing or cytology at six and twelve months in women over 25 — with treatment considered if it persists beyond two years or the patient is significantly anxious.
CIN2 is treated with LEEP or cold-knife conisation, particularly when p16 is diffusely positive or the lesion involves more than two quadrants. In women who wish to preserve fertility, careful observation with colposcopy and co-testing at six months is an option, proceeding to surgery if it progresses. In pregnancy, treatment is deferred to six to eight weeks postpartum.
CIN3 is treated with excision. Where margins are negative, high-risk HPV testing at twelve months is the follow-up test. Positive margins warrant repeat colposcopy and ECC at two to four months, and re-excision or hysterectomy if disease persists. Recurrence after treatment runs 6 to 16 percent over five years, and persistent HPV positivity is the strongest predictor.
Quality control
The guideline also sets service standards — cytology rescreening rates, colposcopy-histology concordance targets, pathologist double-reporting of high-grade disease, and telepathology review within 48 hours — because the accuracy of the pathway depends on the laboratory as much as on the clinic.
Sources and further reading
One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.
General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.





